Logo image of ESPR

ESPERION THERAPEUTICS INC (ESPR) Stock Fundamental Analysis

USA - NASDAQ:ESPR - US29664W1053 - Common Stock

2.84 USD
+0.05 (+1.79%)
Last: 9/12/2025, 8:00:02 PM
2.8401 USD
0 (0%)
After Hours: 9/12/2025, 8:00:02 PM
Fundamental Rating

2

ESPR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ESPR have multiple concerns. ESPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ESPR had negative earnings in the past year.
In the past year ESPR has reported a negative cash flow from operations.
In the past 5 years ESPR always reported negative net income.
In the past 5 years ESPR always reported negative operating cash flow.
ESPR Yearly Net Income VS EBIT VS OCF VS FCFESPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

ESPR's Return On Assets of -29.97% is in line compared to the rest of the industry. ESPR outperforms 51.53% of its industry peers.
Industry RankSector Rank
ROA -29.97%
ROE N/A
ROIC N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESPR Yearly ROA, ROE, ROICESPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

ESPR has a Gross Margin of 61.59%. This is in the better half of the industry: ESPR outperforms 69.39% of its industry peers.
ESPR's Gross Margin has been stable in the last couple of years.
ESPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
ESPR Yearly Profit, Operating, Gross MarginsESPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ESPR has more shares outstanding
ESPR has more shares outstanding than it did 5 years ago.
ESPR has a better debt/assets ratio than last year.
ESPR Yearly Shares OutstandingESPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ESPR Yearly Total Debt VS Total AssetsESPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ESPR has an Altman-Z score of -5.65. This is a bad value and indicates that ESPR is not financially healthy and even has some risk of bankruptcy.
ESPR has a worse Altman-Z score (-5.65) than 60.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.65
ROIC/WACCN/A
WACC9.49%
ESPR Yearly LT Debt VS Equity VS FCFESPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

2.3 Liquidity

ESPR has a Current Ratio of 1.15. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
ESPR's Current ratio of 1.15 is on the low side compared to the rest of the industry. ESPR is outperformed by 78.57% of its industry peers.
ESPR has a Quick Ratio of 1.15. This is a bad value and indicates that ESPR is not financially healthy enough and could expect problems in meeting its short term obligations.
ESPR has a Quick ratio of 0.76. This is amonst the worse of the industry: ESPR underperforms 82.14% of its industry peers.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 0.76
ESPR Yearly Current Assets VS Current LiabilitesESPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.02% over the past year.
Looking at the last year, ESPR shows a decrease in Revenue. The Revenue has decreased by -3.49% in the last year.
Measured over the past years, ESPR shows a quite strong growth in Revenue. The Revenue has been growing by 17.50% on average per year.
EPS 1Y (TTM)43.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.94%
Revenue 1Y (TTM)-3.49%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%11.58%

3.2 Future

Based on estimates for the next years, ESPR will show a very strong growth in Earnings Per Share. The EPS will grow by 45.06% on average per year.
Based on estimates for the next years, ESPR will show a quite strong growth in Revenue. The Revenue will grow by 18.83% on average per year.
EPS Next Y42.3%
EPS Next 2Y18.08%
EPS Next 3Y16.77%
EPS Next 5Y45.06%
Revenue Next Year10.22%
Revenue Next 2Y1.13%
Revenue Next 3Y6.31%
Revenue Next 5Y18.83%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESPR. In the last year negative earnings were reported.
Also next year ESPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESPR Price Earnings VS Forward Price EarningsESPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESPR Per share dataESPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ESPR's earnings are expected to grow with 16.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.08%
EPS Next 3Y16.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ESPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESPERION THERAPEUTICS INC

NASDAQ:ESPR (9/12/2025, 8:00:02 PM)

After market: 2.8401 0 (0%)

2.84

+0.05 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners59.45%
Inst Owner Change-3.71%
Ins Owners0.43%
Ins Owner Change0.52%
Market Cap572.60M
Analysts77.14
Price Target5.92 (108.45%)
Short Float %11.29%
Short Ratio4.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.77%
Min EPS beat(2)-32.97%
Max EPS beat(2)86.52%
EPS beat(4)3
Avg EPS beat(4)24.32%
Min EPS beat(4)-32.97%
Max EPS beat(4)86.52%
EPS beat(8)5
Avg EPS beat(8)81.14%
EPS beat(12)8
Avg EPS beat(12)56.84%
EPS beat(16)11
Avg EPS beat(16)44.72%
Revenue beat(2)2
Avg Revenue beat(2)22.69%
Min Revenue beat(2)17.27%
Max Revenue beat(2)28.11%
Revenue beat(4)3
Avg Revenue beat(4)13.51%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)28.11%
Revenue beat(8)7
Avg Revenue beat(8)23.82%
Revenue beat(12)9
Avg Revenue beat(12)15.29%
Revenue beat(16)12
Avg Revenue beat(16)14.05%
PT rev (1m)0.25%
PT rev (3m)0.25%
EPS NQ rev (1m)-294.66%
EPS NQ rev (3m)-33.63%
EPS NY rev (1m)25.28%
EPS NY rev (3m)31.49%
Revenue NQ rev (1m)-19.12%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)3.56%
Revenue NY rev (3m)5.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS1.33
BVpS-2.15
TBVpS-2.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.59%
FCFM N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
F-Score1
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.55%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 0.76
Altman-Z -5.65
F-Score1
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.94%
EPS Next Y42.3%
EPS Next 2Y18.08%
EPS Next 3Y16.77%
EPS Next 5Y45.06%
Revenue 1Y (TTM)-3.49%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%11.58%
Revenue Next Year10.22%
Revenue Next 2Y1.13%
Revenue Next 3Y6.31%
Revenue Next 5Y18.83%
EBIT growth 1Y-811.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.19%
EBIT Next 3Y7.34%
EBIT Next 5Y45.72%
FCF growth 1Y24.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.38%
OCF growth 3YN/A
OCF growth 5YN/A